Comprehensive Tool Development for the National Covid-19 Effort

我们正在开发一系列全面的关键试剂，以帮助国内和国际对抗新冠肺炎的努力。新冠肺炎是人们记忆中社会面临的最大挑战。这种病毒已经感染了数百万人，并导致全球100多万人死亡。在英国，新冠肺炎的感染率一直位居世界前列。SARS-CoV-2病毒是一种人们知之甚少的冠状病毒。目前还没有批准的药物或疫苗来管理新冠肺炎病。疫苗效力的不确定性使药物和疫苗的开发同时进行，这对疾病管理至关重要。为了实现这一目标，需要对病毒发病机制有更多的了解，只有通过收集先进的试剂作为研究工具和生物标志物才能做到这一点。在与格拉斯哥的CVR协商后，我们及早对新冠肺炎构成的全球威胁做出了反应，并开始设计和生产所有必要的关键生物试剂，以便能够在全国范围内抗击SARS-CoV-2。虽然我们没有资金来实现这一点，但我们强烈认为，我们需要利用我们的专业知识和资源，确保全国各地的研究人员能够获得所需的关键工具。我们已经生产了一系列DNA结构，使研究人员能够表达组成病毒的蛋白质，并在生命系统中研究病毒。我们还生产了组成摄取病毒的28种蛋白质本身，以及类似疾病(SARS和MERS)的一些相关蛋白质。我们还制作了一系列针对病毒全部28个部分的抗体，以帮助研究人员在一系列不同的程序中。我们已经进行了质量检查，并通过我们的网站https://mrcppu-covid.bio.向更广泛的研究社区提供了所有试剂我们将应用成本回收来收回部分试剂供应成本，但需要捐款才能完成我们的工作，并支持在当地工作的科学家实现这一项目。

We are developing a comprehensive range of key reagents to aid the National and International effort against Covid-19. Covid-19 is the biggest challenge society has faced in living memory. The virus has infected many millions of people and killed over a million worldwide. In the UK, the infection rate has been among the highest in the world.The cause of Covid-19 is the virus SARS-CoV-2 virus which belongs to a poorly understood class of coronaviruses. There is currently no approved drug nor vaccine for managing Covid-19 disease. Uncertainty on the efficacy of a vaccine makes parallel efforts into both drug and vaccine development of paramount importance for disease management. To achieve this, more understanding on viral pathogenesis is necessary, only achievable with advanced collections of reagents to act as research tools and biomarkers.In consultation with the CVR in Glasgow, we responded early to the global threat posed by Covid-19 and started to design and produce all the key biological reagents necessary to enable to the national effort against SAR-CoV-2. While we did not have funding in place to enable this, we felt strongly that we needed to use our expertise and resources to ensure that researchers across the country had access to the key tools needed. We have produced a range of DNA constructs to allow researchers to express the proteins that make up the virus and to study the virus in living systems. We have also produced the 28 proteins themselves that make up the uptake virus as well as some related ones from similar diseases (SARS and MERS). We have also made a range of antibodies against all 28 parts of the virus to help researchers in a range of different procedures. We have quality checked and made available all the reagents to the wider research community via our websitehttps://mrcppu-covid.bio. We will apply a cost recovery to recoup some of the reagent costs of supply but need a contribution in order to finish our work and support the scientists who have worked over local down to make this project happen.